Progesterone and Cervical Pessary in Twins (PRECEPET)
Preterm Birth, Twin Pregnancy With Antenatal Problem

About this trial
This is an interventional prevention trial for Preterm Birth focused on measuring twin short cervix pessary progesterone preterm birth
Eligibility Criteria
Inclusion Criteria:
- Twin pregnancy ( dichorionic or monochorionic diamniotic)
- Both fetuses alive
- Asymptomatic short cervix according to gestational age ( measurement less or equal 30 mm between 16 weeks + 0 day and 22 weeks + 0 day, less or equal 25 mm between 22 weeks + 1 day and 24 weeks + 0 day and less or equal 20 mm between 24 weeks + 1 day and 27 weeks + 6 days)
- Gestational age between 16 to 27weeks and 6 days
- Intact membranes
- Informed consent
Exclusion Criteria:
- Monoamniotic twins
- Twin Twin transfusion syndrome
- Rupture membranes
- Major malformation or chromosomal abnormality at least one fetus
- Women with Cervical cerclage in the current pregnancy
- Ballooning of membranes outside the cervix into the vagina
- Placenta previa
- Treatment with progesterone before randomization
- Allergy of the excipientes of the micronized progesterone
- Labor
- Severe hepatic disfunction, porphyria, otosclerosis, severe depression
- Use of drugs that interfere the effects of progesterone
Sites / Locations
- Hospital das Clinicas da FMUSPRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
No Intervention
Progesterone
Arabin Pessary and Progesterone
Arabin Pessary
No intervention
400 mg micronized vaginal progesterone daily from randomization to 36 weeks
Arabin Pessary and Natural Micronized Progesterone 400 mg micronized vaginal progesterone daily from randomization to 36 weeks The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone.
The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
Expectant management